JP2010514725A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514725A5
JP2010514725A5 JP2009543441A JP2009543441A JP2010514725A5 JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5 JP 2009543441 A JP2009543441 A JP 2009543441A JP 2009543441 A JP2009543441 A JP 2009543441A JP 2010514725 A5 JP2010514725 A5 JP 2010514725A5
Authority
JP
Japan
Prior art keywords
methanone
methanesulfonyl
trifluoro
trifluoromethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009543441A
Other languages
English (en)
Japanese (ja)
Other versions
JP4799666B2 (ja
JP2010514725A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/064104 external-priority patent/WO2008080821A1/en
Publication of JP2010514725A publication Critical patent/JP2010514725A/ja
Publication of JP2010514725A5 publication Critical patent/JP2010514725A5/ja
Application granted granted Critical
Publication of JP4799666B2 publication Critical patent/JP4799666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009543441A 2006-12-28 2007-12-18 結晶形態のglyt1 Active JP4799666B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
EP06127269.6 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (3)

Publication Number Publication Date
JP2010514725A JP2010514725A (ja) 2010-05-06
JP2010514725A5 true JP2010514725A5 (enExample) 2010-12-02
JP4799666B2 JP4799666B2 (ja) 2011-10-26

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543441A Active JP4799666B2 (ja) 2006-12-28 2007-12-18 結晶形態のglyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577502A (en) 2006-12-28 2012-02-24 Hoffmann La Roche Crystalline forms glyt1
JP6074142B2 (ja) 2009-02-26 2017-02-01 タール ファーマシューティカルズ,インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
BR112014028872A2 (pt) * 2012-05-25 2017-06-27 Basf Se forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
EP4087570A4 (en) 2020-01-09 2024-04-03 Disc Medicine, Inc. METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
JP7096958B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
EP4337199A4 (en) * 2021-05-14 2025-03-19 Disc Medicine, Inc. Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents
US20240390362A1 (en) * 2021-05-27 2024-11-28 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
NZ577502A (en) 2006-12-28 2012-02-24 Hoffmann La Roche Crystalline forms glyt1

Similar Documents

Publication Publication Date Title
RU2009124113A (ru) Кристаллические формы glyt1
ES2351958T3 (es) 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis.
HRP20231533T1 (hr) Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave
ME02747B (me) Kristalni oblik gama ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
JP2016528179A (ja) 製造方法及びmdm2阻害剤の結晶形
JP2009534373A5 (enExample)
PT2651890E (pt) Derivados de estrigolactama e sua utilização como reguladores do crescimento das plantas
JP2018503662A5 (enExample)
JP2014510133A (ja) 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法
ME02750B (me) Kristalni oblik gama - d iv abradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
JP2020502224A5 (enExample)
JP2018531280A5 (enExample)
JP2005520819A5 (enExample)
JP2016510768A5 (enExample)
JP2019516749A5 (enExample)
EP3337485A1 (en) Crystalline forms of ibrutinib
JP2016539136A5 (enExample)
JP2007519697A5 (enExample)
RU2018103172A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
JP2005529084A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2022535870A (ja) Cdk9阻害剤の結晶多形体及びその製造方法と用途
CN101985444B (zh) 盐酸法舒地尔的v晶型及其制备方法和用途
JP2015531354A (ja) ジヒドロピリミジン誘導体の結晶形
JP2020503330A5 (enExample)